

Martha Sedegah

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/662873/publications.pdf>

Version: 2024-02-01

45
papers

1,079
citations

471509

17
h-index

414414

32
g-index

46
all docs

46
docs citations

46
times ranked

1264
citing authors

#	ARTICLE	IF	CITATIONS
1	Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight, 2017, 2, e89154.	5.0	195
2	DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity. PLoS ONE, 2013, 8, e55571.	2.5	127
3	Ad35.CS.01 - RTS,S/AS01 Heterologous Prime Boost Vaccine Efficacy against Sporozoite Challenge in Healthy Malaria-Naïve Adults. PLoS ONE, 2015, 10, e0131571.	2.5	97
4	Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults. PLoS ONE, 2011, 6, e24586.	2.5	63
5	Sterile Immunity to Malaria after DNA Prime/Adenovirus Boost Immunization Is Associated with Effector Memory CD8+T Cells Targeting AMA1 Class I Epitopes. PLoS ONE, 2014, 9, e106241.	2.5	58
6	Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. Npj Vaccines, 2021, 6, 84.	6.0	52
7	Persistence of Protective Immunity to Malaria Induced by DNA Priming and Poxvirus Boosting: Characterization of Effector and Memory CD8+T-Cell Populations. Infection and Immunity, 2002, 70, 3493-3499.	2.2	38
8	T-cell responses against Malaria: Effect of parasite antigen diversity and relevance for vaccine development. Vaccine, 2018, 36, 2237-2242.	3.8	37
9	Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development. PLoS ONE, 2015, 10, e0136109.	2.5	36
10	Development of whole sporozoite malaria vaccines. Expert Review of Vaccines, 2017, 16, 45-54.	4.4	32
11	Identification of minimal human MHC-restricted CD8+ T-cell epitopes within the Plasmodium falciparum circumsporozoite protein (CSP). Malaria Journal, 2013, 12, 185.	2.3	30
12	Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection. Human Vaccines and Immunotherapeutics, 2013, 9, 2165-2177.	3.3	30
13	Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. Malaria Journal, 2016, 15, 377.	2.3	29
14	A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults. Journal of Infectious Diseases, 2020, 222, 1681-1691.	4.0	29
15	Successful Induction of CD8 T Cell-Dependent Protection Against Malaria by Sequential Immunization with DNA and Recombinant Poxvirus of Neonatal Mice Born to Immune Mothers. Journal of Immunology, 2003, 171, 3148-3153.	0.8	26
16	Vaxfectin [®] enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine, 2006, 24, 1921-1927.	3.8	20
17	IMRAS [®] A clinical trial of mosquito-bite immunization with live, radiation-attenuated P. falciparum sporozoites: Impact of immunization parameters on protective efficacy and generation of a repository of immunologic reagents. PLoS ONE, 2020, 15, e0233840.	2.5	20
18	Ex vivo tetramer staining and cell surface phenotyping for early activation markers CD38 and HLA-DR to enumerate and characterize malaria antigen-specific CD8+ T-cells induced in human volunteers immunized with a Plasmodium falciparum adenovirus-vectored malaria vaccine expressing AMA1. Malaria Journal, 2013, 12, 376.	2.3	18

#	ARTICLE	IF	CITATIONS
19	Vaxfectin® enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses. <i>Vaccine</i> , 2010, 28, 3055-3065.	3.8	14
20	Vaccine Strain-Specificity of Protective HLA-Restricted Class 1 P. falciparum Epitopes. <i>PLoS ONE</i> , 2016, 11, e0163026.	2.5	14
21	Seroprevalence of Antibodies against Plasmodium falciparum Sporozoite Antigens as Predictive Disease Transmission Markers in an Area of Ghana with Seasonal Malaria Transmission. <i>PLoS ONE</i> , 2016, 11, e0167175.	2.5	14
22	Development of replication-deficient adenovirus malaria vaccines. <i>Expert Review of Vaccines</i> , 2017, 16, 261-271.	4.4	14
23	New gorilla adenovirus vaccine vectors induce potent immune responses and protection in a mouse malaria model. <i>Malaria Journal</i> , 2017, 16, 263.	2.3	13
24	Measurement of ex vivo ELISpot interferon-gamma recall responses to Plasmodium falciparum AMA1 and CSP in Ghanaian adults with natural exposure to malaria. <i>Malaria Journal</i> , 2016, 15, 55.	2.3	12
25	A three-antigen Plasmodium falciparum DNA prime-boost Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults. <i>PLoS ONE</i> , 2021, 16, e0256980.	2.5	10
26	The Ex Vivo IFN- γ Enzyme-Linked Immunospot (ELISpot) Assay. <i>Methods in Molecular Biology</i> , 2015, 1325, 197-205.	0.9	9
27	Antibody-Dependent, Gamma Interferon-Independent Sterilizing Immunity Induced by a Subunit Malaria Vaccine. <i>Infection and Immunity</i> , 2019, 87, .	2.2	6
28	IMRAS-Immune Immunization with radiation-attenuated Plasmodium falciparum sporozoites by mosquito bite: Cellular immunity to sporozoites, CSP, AMA1, TRAP and CelTOS. <i>PLoS ONE</i> , 2021, 16, e0256396.	2.5	6
29	Immunological Responses of Neonates and Infants to DNA Vaccines. , 2006, 127, 239-252.		4
30	Controlled Human Malaria Infection (CHMI) differentially affects cell-mediated and antibody responses to CSP and AMA1 induced by adenovirus vaccines with and without DNA-priming. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2705-2715.	3.3	4
31	Identification of Plasmodium falciparum circumsporozoite protein-specific CD8+ T cell epitopes in a malaria exposed population. <i>PLoS ONE</i> , 2020, 15, e0228177.	2.5	4
32	Comparative analysis of the ex vivo IFN-gamma responses to CD8+ T cell epitopes within allelic forms of PfAMA1 in subjects with natural exposure to malaria. <i>PLoS ONE</i> , 2021, 16, e0257219.	2.5	3
33	Towards large-scale identification of HLA-restricted T cell epitopes from four vaccine candidate antigens in a malaria endemic community in Ghana. <i>Vaccine</i> , 2022, 40, 757-764.	3.8	3
34	Decrease in circulating CD25 hi Foxp3 + regulatory T cells following vaccination with the candidate malaria vaccine RTS,S. <i>Vaccine</i> , 2016, 34, 4618-4625.	3.8	2
35	Antigenicity and immune correlate assessment of seven Plasmodium falciparum antigens in a longitudinal infant cohort from northern Ghana. <i>Scientific Reports</i> , 2019, 9, 8621.	3.3	2
36	Novel malaria antigen Plasmodium yoelii E140 induces antibody-mediated sterile protection in mice against malaria challenge. <i>PLoS ONE</i> , 2020, 15, e0232234.	2.5	2

#	ARTICLE	IF	CITATIONS
37	Comparison of the impact of allelic polymorphisms in PfAMA1 on the induction of T Cell responses in high and low malaria endemic communities in Ghana. <i>Malaria Journal</i> , 2021, 20, 367.	2.3	2
38	Cellular immune response to DNA and vaccinia prime-boost immunization kills <i>Plasmodium yoelii</i> -infected hepatocytes in vitro. <i>Pathogens and Disease</i> , 2017, 75, .	2.0	1
39	An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant <i>Plasmodium falciparum</i> in a controlled human malaria infection model. <i>Malaria Journal</i> , 2020, 19, 336.	2.3	1
40	Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein. <i>PLoS ONE</i> , 2015, 10, e0141141.	2.5	1
41	CHARM: COVID-19 Health Action Response for Marinesâ€“Association of antigen-specific interferon-gamma and IL2 responses with asymptomatic and symptomatic infections after a positive qPCR SARS-CoV-2 test. <i>PLoS ONE</i> , 2022, 17, e0266691.	2.5	1
42	Title is missing!. , 2020, 15, e0228177.		0
43	Title is missing!. , 2020, 15, e0228177.		0
44	Title is missing!. , 2020, 15, e0228177.		0
45	Title is missing!. , 2020, 15, e0228177.		0